BlackRock’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-3,742,774
| Closed | -$125M | – | 5877 |
|
|
2026
Q1 | $125M | Sell |
3,742,774
-128,865
| -3% | -$5.05M | ﹤0.01% | 1964 |
|
|
2025
Q4 | $179M | Buy |
3,871,639
+379,387
| +11% | +$20.8M | ﹤0.01% | 1754 |
|
|
2025
Q3 | $236M | Buy |
3,492,252
+647,505
| +23% | +$48M | ﹤0.01% | 1570 |
|
|
2025
Q2 | $238M | Buy |
2,844,747
+931,421
| +49% | +$69.7M | ﹤0.01% | 1520 |
|
|
2025
Q1 | $137M | Sell |
1,913,326
-96,464
| -5% | -$4.7M | ﹤0.01% | 1809 |
|
|
2024
Q4 | $90.3M | Sell |
2,009,790
-2,027
| -0.1% | -$105K | ﹤0.01% | 2138 |
|
|
2024
Q3 | $102M | Buy |
2,011,817
+148,363
| +8% | +$7.1M | ﹤0.01% | 2080 |
|
|
2024
Q2 | $76M | Buy |
1,863,454
+1,537,156
| +471% | +$65.1M | ﹤0.01% | 2193 |
|
|
2024
Q1 | $14M | Buy |
326,298
+12,637
| +4% | +$572K | ﹤0.01% | 3177 |
|
|
2023
Q4 | $12.6M | Buy |
313,661
+313,408
| +123,877% | +$8.92M | ﹤0.01% | 3270 |
|
|
2023
Q3 | $7.47K | Sell |
253
-89
| -26% | -$539 | ﹤0.01% | 5219 |
|
|
2023
Q2 | $1.47K | Hold |
342
| – | – | ﹤0.01% | 5385 |
|
|
2023
Q1 | $731 | Hold |
342
| – | – | ﹤0.01% | 5476 |
|
|
2022
Q4 | $677 | Hold |
342
| – | – | ﹤0.01% | 5655 |
|
|
2022
Q3 | $0 | Sell |
342
-2
| -0.6% | -$5 | ﹤0.01% | 5914 |
|
|
2022
Q2 | $1K | Sell |
344
-8,344
| -96% | -$23.1K | ﹤0.01% | 5811 |
|
|
2022
Q1 | $29K | Sell |
8,688
-401
| -4% | -$2.08K | ﹤0.01% | 5514 |
|
|
2021
Q4 | $56K | Buy |
9,089
+437
| +5% | +$4.58K | ﹤0.01% | 5384 |
|
|
2021
Q3 | $120K | Buy |
8,652
+7,759
| +869% | +$108K | ﹤0.01% | 5096 |
|
|
2021
Q2 | $16K | Sell |
893
-198,086
| -100% | -$3.35M | ﹤0.01% | 5310 |
|
|
2021
Q1 | $3.76M | Buy |
198,979
+3,423
| +2% | +$110K | ﹤0.01% | 4072 |
|
|
2020
Q4 | $5.66M | Buy |
195,556
+15,868
| +9% | +$458K | ﹤0.01% | 3648 |
|
|
2020
Q3 | $6.76M | Buy |
179,688
+76,676
| +74% | +$2.24M | ﹤0.01% | 3440 |
|
|
2020
Q2 | $3.43M | Buy |
103,012
+97,296
| +1,702% | +$4.22M | ﹤0.01% | 3664 |
|
|
2020
Q1 | $205K | Buy |
5,716
+1,152
| +25% | +$49K | ﹤0.01% | 4224 |
|
|
2019
Q4 | $201K | Sell |
4,564
-37
| -0.8% | -$947 | ﹤0.01% | 4317 |
|
|
2019
Q3 | $103K | Sell |
4,601
-203
| -4% | -$6.48K | ﹤0.01% | 4439 |
|
|
2019
Q2 | $202K | Buy |
4,804
+2,221
| +86% | +$76.8K | ﹤0.01% | 4366 |
|
|
2019
Q1 | $80K | Sell |
2,583
-104
| -4% | -$2.76K | ﹤0.01% | 4408 |
|
|
2018
Q4 | $69K | Sell |
2,687
-32
| -1% | -$934 | ﹤0.01% | 4422 |
|
|
2018
Q3 | $88K | Buy |
2,719
+68
| +3% | +$2.47K | ﹤0.01% | 4471 |
|
|
2018
Q2 | $93K | Buy |
2,651
+1,611
| +155% | +$47.2K | ﹤0.01% | 4469 |
|
|
2018
Q1 | $28K | Hold |
1,040
| – | – | ﹤0.01% | 4523 |
|
|
2017
Q4 | $28K | Hold |
1,040
| – | – | ﹤0.01% | 4513 |
|
|
2017
Q3 | $41K | Buy |
1,040
+5
| +0.5% | +$197 | ﹤0.01% | 4509 |
|
|
2017
Q2 | $39K | Buy |
1,035
+7
| +0.7% | +$324 | ﹤0.01% | 4558 |
|
|
2017
Q1 | $54K | Buy |
+1,028
| New | +$60.6K | ﹤0.01% | 4457 |
|
BlackRock's SLNO Position: Q2 2026 in Review
BlackRock sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 3,742,774 shares — an estimated $125M sold.
BlackRock first reported a position in SLNO in Q1 2017 and held it in 37 quarters. The position peaked at $238M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- BlackRock reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- BlackRock sold 3,742,774 Soleno Therapeutics shares in Q2 2026, an estimated $125M.
- BlackRock first reported a position in Soleno Therapeutics in Q1 2017 and held it in 37 quarters.
- BlackRock's Soleno Therapeutics position peaked at $238M in Q2 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.